Pemphigus in the Arab world

Journal of Dermatology

Volumn 42, Issue 1, 2015, Pages 27-30

  Saleh, Marwah A ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Arab; autoimmune bullous disease; epidemiology; pemphigus foliaceus; pemphigus vulgaris

Indexed keywords

COSMETIC; DESMOGLEIN 1 ANTIBODY; DESMOGLEIN 3 ANTIBODY; STEROID;

ADJUVANT THERAPY; AGE; AGRICULTURAL WORKER; ARAB; CITY; DEMOGRAPHY; DESERT; EGYPT; ENDEMIC DISEASE; ENVIRONMENTAL FACTOR; FOREST; GENDER; HUMAN; INCIDENCE; KUWAIT; LANGUAGE; LATITUDE; LIBYAN ARAB JAMAHIRIYA; MAINTENANCE DRUG DOSE; MOROCCO; PATHOGENESIS; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PHENOTYPE; PREVALENCE; REVIEW; RISK FACTOR; SAUDI ARABIA; STEROID THERAPY; SUDAN; SYRIAN ARAB REPUBLIC; TUNISIA; TUNISIAN; YEMEN; ARAB WORLD;

ARAB WORLD; HUMANS; PEMPHIGUS;

EID: 84920546961     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12676     Document Type: Review

References (30)

1. Twegry MI,. Arab Countries Figures and Indicators, 4th edn. Economic and statistical databases sector of the League of Arab Countries, 2013.
2. Amagai M, Tsunoda K, Zillikens D, et al,. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol 1999; 40: 167-170.
3. Benchikhi H, Ghafour S, Disky A, et al,. Pemphigus: analysis of 262 cases. Int J Dermatol 2008; 47: 973-975.
4. Bastuji-Garin S, Souissi R, Blum L, et al,. Comparative epidemiology of pemphigus in Tunisia and France: unusual incidence of pemphigus foliaceus in young Tunisian women. J Invest Dermatol 1995; 104: 302-305.
5. Alsaleh QA, Nanda A, Al-Baghli NM, et al,. Pemphigus in Kuwait. Int J Dermatol 1999; 38: 351-356.
6. Shafi MKML, Mashina M, Ben-Ghazeil M,. Pemphigus: a clinical study of 109 cases from Tripoli, Libya. Indian J Dermatol Venereol Leprol 1994; 60: 140-143.
7. Suliman NM, Astrom AN, Ali RW, et al,. Clinical and histological characterization of oral pemphigus lesions in patients with skin diseases: a cross sectional study from Sudan. BMC Oral Health 2013; 13: 66.
8. Tallab T, Joharji H, Bahamdan K, et al,. The incidence of pemphigus in the southern region of Saudi Arabia. Int J Dermatol 2001; 40: 570-572.
9. Brick C, Belgnaoui FZ, Atouf O, et al,. Pemphigus and HLA in Morocco. Transfus Clin Biol 2007; 14: 402-406.
10. Harfouch E, Daoud S,. Allelic variation in HLA-DRB1∗ loci in Syrian pemphigus vulgaris patients. Int J Dermatol 2014; doi: 10.1111/ijd.12184.
11. Lal Khatri M,. Spectrum of skin diseases in Yemen (Hajjah and adjacent region). Int J Dermatol 2004; 43: 580-585.
12. Abida O, Zitouni M, Kallel-Sellami M, et al,. Tunisian endemic pemphigus foliaceus is associated with the HLA-DR3 gene: anti-desmoglein 1 antibody-positive healthy subjects bear protective alleles. Br J Dermatol 2009; 161: 522-527.
13. AL-abdulla H, Selim MM, Kamal A, Mansour K,. Pattern of Skin diseases in Qatar. Gulf J Dermatol 1995; 2: 1-13.
14. Amal S, Hocar O, Zidane W, et al,. [Epidemiologic study of pemphigus in Marrakech: 134 cases]. Ann Dermatol Venereol 2005; 132: 1008-1009.
15. Zaraa I, Kerkeni N, Ishak F, et al,. Spectrum of autoimmune blistering dermatoses in Tunisia: an 11-year study and a review of the literature. Int J Dermatol 2011; 50: 939-944.
16. Nanda A, Dvorak R, Al-Saeed K, et al,. Spectrum of autoimmune bullous diseases in Kuwait. Int J Dermatol 2004; 43: 876-881.
17. Saleh MA, El-Bahy MM,. Do normal Egyptians possess anti-desmoglein 3 antibodies? Int J Dermatol 2014; doi: 10.1111/ijd.12662.
18. Bastuji-Garin S, Turki H, Mokhtar I, et al,. Possible relation of Tunisian pemphigus with traditional cosmetics: a multicenter case-control study. Am J Epidemiol 2002; 155: 249-256.
19. Abida O, Kallel-Sellami M, Joly P, et al,. Anti-desmoglein 1 antibodies in healthy related and unrelated subjects and patients with pemphigus foliaceus in endemic and non-endemic areas from Tunisia. J Eur Acad Dermatol Venereol 2009; 23: 1073-1078.
20. Khaled A, Taazayet SB, Ben Alaya N, et al,. The course and prognosis of pemphigus in 47 Tunisian patients. J Eur Acad Dermatol Venereol 2013; 27: 81-85.
21. Benchikhi H, Ghafour S, Disky A, et al,. [Pemphigus: treatment and outcome in 122 cases]. Ann Dermatol Venereol 2006; 133: 1012-1014.
22. Abd EL, Gaber S, Badr R,. Detection of Human Herpes Virus-8 DNA in pemphigus skin lesions. J Egypt Women Dermatol Society 2007; 4: 561-564.
23. el-Darouti M, Marzouk S, Abdel HR, et al,. The use of sulfasalazine and pentoxifylline (low-cost antitumour necrosis factor drugs) as adjuvant therapy for the treatment of pemphigus vulgaris: a comparative study. Br J Dermatol 2009; 161: 313-319.
24. Kronfol NM,. Access and barriers to health care delivery in Arab countries: a review. East Mediterr Health J 2012; 18: 1239-1246.
25. Pasricha JS, Thanzama J, Khan UK,. Intermittent high-dose dexamethasone-cyclophosphamide therapy for pemphigus. Br J Dermatol 1988; 119: 73-77.
26. Shahidi-Dadras M, Karami A, Toosy P, et al,. Pulse versus oral methylprednisolone therapy in pemphigus vulgaris. Arch Iran Med 2007; 10: 1-6.
27. El Malla H, Ylitalo Helm N, Wilderang U, et al,. Adherence to medication: a nation-wide study from the Children's Cancer Hospital, Egypt. World J Psychiatry 2013; 3: 25-33.
28. Al-Qasem A, Smith F, Clifford S,. Adherence to medication among chronic patients in Middle Eastern countries: review of studies. East Mediterr Health J 2011; 17: 356-363.
29. Nanda M, Nanda A, Al-Sabah H, et al,. Paraneoplastic pemphigus in association with B-cell lymphocytic leukemia and hepatitis C: favorable response to intravenous immunoglobulins and prednisolone. Int J Dermatol 2007; 46: 767-769.
30. Saleh MA,. Correlation of pemphigus disease area index and anti-desmoglein antibody index in pemphigus vulgaris patients. J Egypt Women Dermatol Society 2013; 10: 120-124.